1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology
  4. > Biopharmaceutical Market Trends
Global Interferon Market & Pipeline Analysis 2015

Global Interferon Market & Pipeline Analysis 2015

  • April 2015
  • 230 pages
  • ID: 4397225
  • Format: PDF
  • Kuick Research

Summary

Table of Contents

Interferons are small, low molecular weight proteins of varying sizes induced during attack by infectious agents like viruses. Investigators have found that they are highly variable in nature and have several subtypes due to which misunderstanding is easily created. Furthermore, they have synergistic effect in which interferons belonging to different classes have same effect on immune system due to sharing of common pathways. These facts gave emphasis on the development of classification system to organize, recognize, associate relationship and differentiate interferons from each other. Moreover, advent of genome sciences is allowing the investigators to look deeper into the DNA sequences that could be used to more clarity to existing classification system. In this way, investigators would be better informed and make suitable changes according to necessities of drug development program.

Interferon segment covers few diseases due to which they have modest market shares in pharmaceutical industry. Infectious diseases, few malignancies and Multiple Sclerosis are their major target group from which they generate revenues. Multiple sclerosis field is one of the highly developed segments which has numerous products and offer better performance than other therapeutics. In infectious diseases, they have significant effect and offers competition to vaccines which are one of the strongest pharmaceutical segments. In this segment, only for limited diseases they have very high pharmacological and commercialization potential due to which they are maintaining dominance in global market. Hepatitis and AIDS-associated disease is one such segment which generates significant revenues. On the other hand, cancer segment shows similar trend but their role in combinatorial therapy can’t be neglected due to which they have become important for treating cancer. Some of them are first-line cancer therapeutics and it is imperative to increase their number to offer sustained competition. In this way, interferons have become indispensible part of several disease segments but limited number of products seems to be the major limiting factor despite their superior pharmacological benefits.

During disease incidence, particular types of interferons or associated molecules are produced in body to provide protection against infectious agents. Interferon based diagnostics are relatively new concept for the market and they are expected to be used for several diseases. Mostly they would be used for identifying infectious disease because of their immunological origin. As a result, they would have higher resolution, precision, accuracy and reproducibility of results. This technology is at nascent stages and it has to face severe competition from already existing diagnostics tests. Besides infectious disease, it could also be used for early cancer diagnosis due to which several lives could be saved. Diagnostically, they will have superior performance but their higher costs may cause some hinderance in their successful commercialization. With time, it is expected that the costs of developmental technology would decrease due to which more patients would be opting them to identify potential diseases.

In past few years, significant investments have been made in research and development segment to come forth with innovative products. It was observed that administration of interferons triggers a cascade of reactions in which some genes are activated. So, emphasis was given on developing higher order organization containing different hierarchy that could be used to extract information related to interferon genes. Knowledge of such genes could be utilized to develop innovative interferon based therapeutics for different diseases. Moreover, it could prevent the undue consumption of time and resources involved in screening of potential interferon candidates for drug development program. Due to their applicability in different diseases it is expected that they would be able to occupy major market shares across the globe. As a result, several therapeutic products are at different stages of clinical trials which will be introduced in global market in coming years.

“Global Interferon Market & Pipeline Analysis 2015” Report Highlights:

Introduction & Classification of Interferons
Interferon Clinical Pipeline Country, Indication & Phase
Interferon Clinical Pipeline: 79 Drugs
Majority Interferon Drugs in Preclinical Phase: 29 Drugs
Marketed Interferon Drugs: 37 Drugs
Marketed Interferon Drug Clinical Insight & Patent Analysis
Global Interferon Market Future Prospects

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on